WO1999058496A1 - Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent - Google Patents
Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent Download PDFInfo
- Publication number
- WO1999058496A1 WO1999058496A1 PCT/FR1999/001101 FR9901101W WO9958496A1 WO 1999058496 A1 WO1999058496 A1 WO 1999058496A1 FR 9901101 W FR9901101 W FR 9901101W WO 9958496 A1 WO9958496 A1 WO 9958496A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- group
- ethyl
- compounds
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/62—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/42—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/92—Naphthofurans; Hydrogenated naphthofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D333/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/74—Naphthothiophenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Definitions
- the present invention relates to new substituted cyclic derivatives, their preparation process and the pharmaceutical compositions containing them.
- Benzofiiranic or benzothiophenic compounds with a retroamide chain substituted by amides or carbamates are also described as anti-inflammatory agents (EP 685475) or inhibitors of bone resorption.
- the compounds of the present invention are new and have very interesting pharmacological characteristics concerning the melatoninergic receptors.
- melatonin N-acetyl-5-methoxytryptamine
- melatonin N-acetyl-5-methoxytryptamine
- it has a fairly short half-life due to rapid metabolism. It is therefore very interesting to be able to make available to the clinician analogues of melatonin, metabolically more stable and having an agonist or antagonist character, from which one can expect a therapeutic effect greater than that of the hormone itself.
- the ligands of the melatoninergic system have interesting properties pharmacological on the central nervous system, in particular anxiolytics and antipsychotics (Neuropharmacology of Pineal Sécrétions, 1990, 8 (3-4), pp 264-272) and analgesics (Pharmacopsychiat., 1987, 20, pp 222-223) as well as for treatment of Parkinson's diseases (J. Neurosurg. 1985, 63, pp 321-341) and Alzheimer's (Brain Research, 1990, 528. pp 170-174).
- the compounds of the present invention in addition to their novelty, show a very strong affinity for the melatonin receptors and / or a selectivity for one or the other of the melatoninergic receptor subtypes.
- the present invention relates more particularly to the compounds of formula (I):
- A represents:
- X represents an oxygen, sulfur or nitrogen atom, or a group C (H) q (where q is 0, 1 or 2), or NRo (in which Ro represents a hydrogen atom, a alkyl (C ⁇ -C6) linear or branched, aryl, aryl (C ⁇ -C6) linear or branched alkyl or SO Ph), • Y represents a nitrogen atom or a group C (H) q (wherein q is 0 , 1 or 2), Z represents a nitrogen atom or a group C (H) q (where q is 0, 1 or 2), X, Y and Z cannot simultaneously represent three heteroatoms,
- B represents a benzene or pyridine ring
- R substitutes the ring B and R 'replaces the ring containing the groups X, Y and Z, or R and R' substitute the ring B
- Y ' represents a group C (H) q (where q is 0, 1 or 2), or NRn where R is as defined above,
- Z ' represents a group C (H) q (where q is 0, 1 or 2), or NRo where Ro is as defined above,
- T represents an oxygen or sulfur atom, or a group C (H) q (where q is 0, 1 or 2),
- n is an integer such that 0 ⁇ n ⁇ 3,
- W represents an oxygen, sulfur or nitrogen atom, or a group [C (H) q ] p (where q is 0, 1 or 2, and p is 1 or 2), or NRo where Ro tel as defined above,
- the ring systems of formulas (II), (III) and (IV) and the biphenyl group may or may not be substituted (in addition to the substituents R and R ') by 1 to 6 radicals, identical or different, chosen from K_, OR a , COR a , COOR a , OCOR a , OSO 2 CF 3 or halogen atoms, where R a represents a hydrogen atom, a linear or branched alkyl group (Ci-Ce) substituted or not, alkenyl (C 2 -C ⁇ ) linear or branched substituted or not, alkynyl (C 2 -C 6 ) linear or branched substituted or not, polyhaloalkyl (C ⁇ -C 6 ) linear or branched, cycloalkyle (C 3 -C 8 ) substituted or not, cycloalkyle (C -C 8 ) alkyl (C I -C ⁇ ) linear or
- C ⁇ -C 6 linear or branched substituted or not, aryl, arylalkyl (C ⁇ -C 6 ) linear or branched, arylalkenyl (C I -C ⁇ ) linear or branched, heteroaryl, heteroarylalkyl (C ⁇ -C 6 ) linear or branched linear or branched heteroarylalkenyl (CC 6 ), linear or branched heterocycloalkyl (CC 6 ) substituted or not, substituted or unsubstituted heterocycloalkenyl, linear or branched heterocycloalkylalkyl (Ci-Ce) or linear or heterocycloalkenyl alkyl (Ci-Ce) branched substituted or not,
- R represents:
- R 1 represents a group NR ' a R " a or OR' a (where R ' a and R" a , identical or different, can take all the values of R a and can also form, with the nitrogen atom which carries them a cyclic grouping containing 5 to 10 links and being able to comprise, in addition to the nitrogen atom by which it is connected, one to three heteroatoms chosen among oxygen, sulfur and nitrogen, and R ' a can take all the values of R a with the exception of the hydrogen atom),
- R 2 represents a group R a as defined above
- R 3 represents a group COR ' a , CSR' a , CONR ' a R " a , CSNR' a R" a , COOR ' a ,
- R 4 represents a group NR ' a R “ a , NR a COR' a , NR a CSR ' a , NR a CONR' a R" a , NR.CSNR ⁇ R “. or NR a COOR ' a , where R ,, R' a and R " a are defined as above,
- A represents a ring system of formula (II) or (III) or a biphenyl group
- (0) v (0) v QRRE represents a group -S— N -, -S— N ⁇ C- - NS- N rC
- R ' a and v are as defined above, the ring formed containing from 5 to 7 atoms and possibly containing 1 to 3 heteroatoms chosen from nitrogen, sulfur and oxygen, one or more unsaturations, and being optionally substituted by one or more radicals, identical or different, chosen from R a , OR a , COR a , COOR a , OCOR a , NR ' a R " a , NR a COR' a , CONR ' a R" a , cyano, oxo, SR a , S (O) R a , SO 2 R a , CSR a , NR a CSR ' a , CSNR' a R " a , NR a CONR ' a R" a , NR a CSNR' a R " a or halogen atoms, where R a , R ' a and R" a , identical or different
- G represents an alene chain - (CH 2 ) t - (in which t is an integer such that 0 ⁇ t ⁇ 4 when A represents a t ⁇ cyclic structure and such that 1 ⁇ t ⁇ 4 when A represents a bicyclic structure), optionally substituted by one or more radicals, identical or different, chosen from R a , OR a , COOR a , COR a (in which R a is as defined above) or atoms of halogen,
- R 5 represents a group - N— C—, - N r— C— NR 'R ", - C ⁇ NR'R" il n aa n
- R ' a and R " a being able to form, with the nitrogen atom which carries them, a cyclic group as defined above,
- heterocycloalkyl means any saturated mono or polycyclic group containing from 5 to 10 atoms containing 1 to 3 heteroatoms chosen from nitrogen, oxygen or sulfur.
- heterocycloalkenyl means any non-aromatic mono or polycyclic group containing one or more unsaturations, containing from 5 to 10 atoms and possibly containing 1 to 3 heteroatoms chosen from nitrogen, oxygen or sulfur,
- alkyl alkenyl
- alkynyl alkynyl
- substituted means that these groups are substituted by one or more radicals, identical or different, chosen from hydroxy, alkoxy (C ⁇ -C 6 ) linear or branched, linear or branched (Ci-C ⁇ ) alkyl, linear or branched polyhaloalkyl (Ci -Ce), amino or halogen atoms,
- heterocycloalkylalkyle means that the cyclic part of these groups is substituted by one or more radicals, identical or different, chosen from hydroxy, alkoxy (C ⁇ -C 6 ) linear or branched, alkyl (C ⁇ -C 6 ) linear or branched, polyhaloalkyl (Cj-C ⁇ ) linear or branched, amino or halogen atoms,
- aryl means any aromatic mono or polycyclic group containing 6 to
- heteroaryl means any mono or polycyclic aromatic group containing from 5 to 10 atoms containing 1 to 3 heteroatoms chosen from nitrogen, oxygen or sulfur,
- aryl and heteroaryl groups which may be substituted by one or more radicals, identical or different, chosen from hydroxy, linear or branched (C ⁇ -C 6 ) alkoxy, linear or branched (Ci-Ce) alkyl, polyhaloalkyl (C ⁇ -C 6 ) linear or branched, cyano, carboxy, nitro, amino or halogen atoms,
- GR 5 cannot represent a group - (CH 2 ) -NHCORb in which Rb represents a group alkyl (CC 4 ) or CF 3 ,
- R when A represents a tetrahydronaphthalene, R cannot represent a group CONR ' a R " a ,
- hydrochloric hydrobromic, sulfuric, phosphonic, acetic, trifluoroacetic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, tartaric, maleic, citric, ascorbic, methanesulfonic, camphoric acids. , oxalic, etc.
- the preferred compounds of the invention are those for which A represents a ring system of formula (II 1 ) B (II 1 ) in which B, X and the representation have the same definition
- the invention relates to compounds wherein A, (unsubstituted or substituted by a single substituent (in addition to R and R '), preferably in 2-position (formula IF) or in 3-position (formula 111 ")
- the invention relates to the compounds for which A, of formula (IF) or (IIF) is substituted by R in positions 5 (formula IF) or 7 (formula III ') and by R' in position 3 (IF formula) or 1 or 2 (IIF formula)
- the preferred substituents R of the invention are those represented by a group of formula (V), (VI) or (VII). More advantageously, the preferred substituents R of the invention are those represented by a group of formula (V) in which Q represents an oxygen atom and R 1 represents a group NR ' a R " a (where R' a and R " a are defined as above) or OR ' a (where R' a is as defined above), a group of formula (VI) in which R 3 represents a group COR ' a or COOR' a (where R ' a is as defined above), or a group of formula (VII) in which v is 2 and R 4 represents a group NR ' a R " a as defined above.
- the preferred substituents R of the invention are those represented by a group CONR ' a R “ a or SO 2 NR' a R" a where R ' a and R " a , identical or different, represent a hydrogen atom or an alkyl, polyhaloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl group, for example methyl, ethyl, propyl, isopropyl, butyl, butyl butyl , pentyl, isopentyl, hexyl, trifluoromethyl, vinyl, allyl, propargyl, phenyl, naphthyl, benzyl, phenethyl, cyclopropyl, cyclobutyl,
- R 'of the invention are those for which G represents a group - (CH) t - where t is 2 or 3, and R 5 represents a group - NHC - R' a where R ' a represents an alkyl, polyhaloalkyl, alkenyl, alkynyl group,
- O represents an alkyl, polyhaloalkyl, alkenyl, alkynyl, cycloakyl, cycloalkenyl, cycloakylalkyl, cycloalkenylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl group, such as, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, butyl , hexyl, trifluoromethyl, vinyl, allyl, propargyl, phenyl, naphthyl, benzyl, phenethyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, methylcyclopropyl, ethylcyclopropyl, furyl, thienyl, pyridyl, furylmethyl, pyridyl.
- the preferred compounds of the invention are those for which A represents a ring system of formula (IF) or (IIF) and R represents a group of formula (V), (VI) or (VII).
- the invention relates to the compounds for which: A represents a group of formula (IF) or (IIF) substituted in position 5 (formula IF) or 7 (formula IIF) by R and in positions 3 (formula IF) or 1 or 2 (formula IIF) by R ', and R represents a group CONR ' a R " a , SO 2 NR' a R" a , COOR ' a , NHCOR' a or NHCOOR ' a (where R' a , R " a and R 1 ;, are as defined above ).
- the preferred compounds of the invention are those for which A represents a ring system of formula (IF) or (IIF) optionally substituted (in addition to R and R ') by a substituent in position 2 (formula IF) or in position 3 (formula IIF), substituted in positions 5 (formula IF) or 7 (formula IIF) by R and in positions 3 (formula IF) or 1 or 2 (formula IIF) by R ', R represents a group CONR ' a R " a , SO 2 NR' a R" a , COOR ' a , NHCOR' a or NHCOOR ' a (where R' a , R " a and R ' a are defined as above), and R' is such that G represents an alkylene chain - (CH 2 ) t - unsubstituted or substituted where t is
- R 5 represents a group - N - C -R ', - N - C -NR' R "or - C - NR 'R"
- R a , R ' a , R " a and Q are as defined above.
- the invention relates to (dihydro) benzothiophene, (dihydro) benzofuran, indole, indoline, indene, indane, azaindole, thieno or furopyridine optionally substituted in position 2, and dihydronaphthalene, tetrahydronaphthalene, naphthalene or chromane optionally substituted in position 3, substituted in 5 (7 respectively) by a group CONR ' a R " a , SO 2 NR' a R" a , COOR ' a , NHCOR'a or NHCOOR'a where R' a and R " a , identical or different represent a hydrogen atom, an alkyl, polyhaloalkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylakyl, aryl, aryl
- the preferred compounds of the invention are: naphthalenes, dihydronaphthalenes or tetrahydronaphthalenes optionally substituted in position 3, substituted in 7 by a group NHCOR a , NHCOOR a , CONHR a or COOR ' a (where
- R a and R ! a are defined as above), and substituted in 1 by a group - (CH 2 ) t -
- NHCOR'a where t is 2 or 3 and R ' a is as defined above, or benzofuran or benzothiophene optionally substituted in position 2, substituted in 5 by a group NHCOR a , NHCOOR a , CONHR a or COOR' a (where R a and R ' a are defined as above), and substituted in 3 by a group - (CH 2 ) NHCOR' a where t is 2 or 3 and R ' a is defined as above.
- the invention relates very particularly to the compounds of formula (I) which are:
- the invention also covers the process for preparing the compounds of formula (I) characterized in that there is used as starting material the compound of formula (X) •
- Hal-AR '(XII) in which A and R' are defined as above and Hal represents a halogen atom the compounds of formula (XII) being obtainable by exchange reactions such as for example the treatment of a derivative chlorinated by KF within dimethylformamide to lead to the corresponding fluorinated derivative, or the treatment of a brominated derivative with K1 in the presence of copper salts to lead to the corresponding iodized derivative,
- compound of formula (XIII) which can moreover be obtained by conventional lithiation techniques from the halogen derivative of formula (XII), or via the corresponding vinyl derivative (obtained from the compound of formula (XII) by the action of vinyltributyltin and palladium tetrakis) subjected to ozonolysis, or also by direct formylation of the nucleus A according to a Vilsmeier reaction for example,
- R ' a is as defined above, or its corresponding anhydride (R' a OCO) 2 O,
- R a , R ' a , R " a , Q, A and R' are as defined above,
- R a , R ' a , A and R' are defined as above,
- the starting compounds (X) are either commercial or described in the literature, for example in applications EP0447285, EP0527687, EP0562956, EP0591057, EP0662471, EP0745586, EP0709371, EP0745583, EP0721938, EP0745584, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP07376682, EP0737
- Another advantageous process of the invention concerning the preparation of the compounds of formula (I) is characterized in that the compound of formula (XXII) is used as starting material: in which R and the representation ____ are defined as above, Y "represents a group C (H) q (where q is 0, 1 or 2) or a bond, and X" represents an atom of oxygen, nitrogen or of sulfur or a group C (H) q (where q is 0, 1 or 2) or NRo (where R > is as defined above) it being understood that when X "represents a nitrogen atom or a group NRo then Y "represents a bond,
- the compounds (F / p) to (F / s) which can be purified according to a conventional separation technique, which is converted, if desired, into their addition salts with a pharmaceutically acceptable acid or base, and from which the isomers are optionally separated according to a conventional separation technique.
- R is as defined above, and X '"represents an oxygen or sulfur atom, or an NRo group (where Ro is as defined above),
- the invention also relates to the process for preparing the compounds of formula (I) for which R represents a cycle of formula (VIII) characterized in that the compounds of formula (I / a) to ( Us), which are cyclized according to methods described in the literature, such as for example in applications EP 0708099 or WO 9732871.
- the compounds of the invention and the pharmaceutical compositions containing them prove to be useful for the treatment of disorders of the melatoninergic system.
- the pharmacological study of the derivatives of the invention has in fact shown that they are non-toxic, endowed with a high affinity for melatonin receptors and have important activities on the central nervous system and, in particular, statement of therapeutic properties on sleep disorders, anxiolytic, antipsychotic, analgesic properties as well as on the microcirculation which make it possible to establish that the products of the invention are useful in the treatment of stress, sleep disorders, anxiety, seasonal depressions, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jet lag, schizophrenia, panic attacks, melancholy, appetite disorders, obesity, insomnia, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders related to normal or pathological aging, migraine, memory loss, Alzheimer's disease, as well as in cerebral circulation disorders.
- the products of the invention can be used in sexual dysfunctions, that they have properties of ovulation inhibitors, of immunomodulators and that they are likely to be used in the treatment
- the compounds will preferably be used in the treatment of seasonal depressions, sleep disorders, cardiovascular pathologies, insomnia and fatigue due to jetlag, appetite disorders and obesity.
- the compounds will be used in the treatment of seasonal depressions and sleep disorders.
- the present invention also relates to pharmaceutical compositions containing at least one compound of formula (I) alone or in combination with one or more pharmaceutically acceptable excipients.
- compositions according to the invention there may be mentioned, more particularly those which are suitable for oral, parenteral, nasal, per. or transcutaneous, rectal, perlingual, ocular or respiratory and in particular the simple or coated tablets, the sublingual tablets, the sachets, the packets, the capsules, the glossettes, the tablets, the suppositories, the creams, the ointments, the dermal gels, and oral or injectable ampoules.
- the dosage varies according to the sex, age and weight of the patient, the route of administration, the nature of the therapeutic indication, or possibly associated treatments and ranges between 0.01 mg and 1 g per 24 hours in 1 or more takes.
- Chlorine (10 mmol) is bubbled into dichlorophenylphosphine at a flow such that the reaction temperature is maintained between 70 and 80 ° C. After complete addition of the chlorine, the phenylphosphine tetrachloride thus obtained is a pale yellow liquid. 10 mmol of the product obtained in Preparation 5 are added in a single portion, and the reaction mixture is heated to 160 ° C overnight. After cooling, the solution is poured into a water / ice mixture (20 ml) and neutralized with a 50% aqueous sodium hydroxide solution. After extraction with ether, the organic phases are dried and concentrated under reduced pressure to give a residue which is chromatographed on silica gel in order to obtain the pure title product.
- Triphenylphosphine (10 mmol) and acetonitrile are poured into a 150 ml three-necked flask fitted with a dropping funnel, a cooler surmounted by a tube filled with calcium chloride, and a mechanical stirrer (70 ml).
- the solution is cooled using an ice bath while stirring and the bromine (10 mmol) is added.
- the ice bath is removed and then the product obtained in Preparation 2 (8 mmol) is added.
- the reaction mixture is stirred at 60-70 ° C until disappearance of the starting product (monitored by TLC).
- the mixture is filtered and the filtrate is concentrated under reduced pressure.
- a solution of the product obtained in stage D (20 mmol) in dichloromethane (30 ml) containing tetrabutyl ammonium bromide (20 mg) is cooled in an ice bath. After adding the sodium azide (24 mmol) dissolved in 5 ml of water, the solution is stirred vigorously at 0 ° C for 2 hours. The organic phase is separated, washed with water (2 x 5 ml) and dried over magnesium sulfate. After filtration, trifluoroacetic acid (30 mmol) is added and the solution is stirred under reflux for 60 hours. After cooling, the organic phase is washed with a saturated solution of sodium hydrogen carbonate (2 x 5 ml) and concentrated under reduced pressure.
- Preparations 135 to 145 are obtained by proceeding as in Preparation 1 from the appropriate substrate.
- Example 4 the procedure is as in Example 1 starting from the appropriate reagents.
- Examples 17 to 23 are obtained by proceeding as in Example 2 from the appropriate reagents.
- Example 31 to 50 the procedure is as in Example 30, but replacing the ethylamine and the product from stage D of Preparation 109 with the appropriate substrates.
- EXAMPLE 45 2 - [( ⁇ 8- [2-Heptanoylamino) ethyl] -6-naphthyl-2-naphthyl ⁇ carbonyl) amino] ethyl acetate
- EXAMPLE 48 2 - ( ⁇ [8- [2- (Acetylamino) ethyl] -6- (cyclopropylmethyl) -2-naphthyl] carbonyI ⁇ amino) ethyl acetate
- Example 32 The product obtained in Example 32 is treated with the Lawesson reagent to yield the title compound.
- Example 52 the procedure is as in Example 51, taking the appropriate starting substrate.
- Example 58 the procedure is as in Example 1, replacing the acid chloride with the corresponding halo carboxylate.
- stage C The compound obtained in stage C (15 mmol) is dissolved in 35 ml of acetone. 30 mmol of potassium carbonate are added and the medium is stirred for 2 hours at ambient temperature. The precipitate formed is filtered, washed with acetone and the filtrate is evaporated under reduced pressure.
- the benzofuranone formed is used directly in the following step:
- the 5- (methoxycarbonyl benzo [/ 3] furan-3-yl) acetonitrile obtained in stage D (6.46 mmol) is dissolved in acetic anhydride (30 ml) and 14.4 mmol of Nickel are dissolved in an autoclave. Raney are added. After stirring overnight at 60 ° C and under a hydrogen pressure of 60 bars, the catalyst is filtered and washed with methanol. The filtrate is evaporated to dryness and the brown precipitate obtained is chromatographed on a column of silica gel with ethyl acetate as eluent then recrystallized.
- stage A The acid (1 mmol) obtained in stage A is dissolved in acetone The temperature of the reaction medium is lowered using an ice bath and triethylamine (1.5 mmol) is added, followed by chloroformate. ethyl (1.5 mmol) After 15 minutes of stirring, sodium azide is added (1.5 mmol) previously dissolved in water (1 ml of water for 400 mg of sodium azide), then the mixture is again stirred for 10 minutes. The medium is extracted with ethyl acetate, then the organic phase is washed with water, dried over magnesium sulfate and evaporated to dryness. The azide obtained is used without further purification, in the next step.
- Stage B 8- [2- (Acetylamino) ethyl] -2-naphthalene sulfonyl chloride
- Example 80 The procedure is as in Example 80, replacing the ammonia in stage C with methylamine.
- Examples 97 to 105 are obtained by proceeding as in Example 1, replacing the acid chloride with the corresponding halogen carboxylate.
- Examples 106 to 108 are obtained by proceeding as in Example 1 from the appropriate substrate.
- Examples 109 to 112 are obtained by proceeding as in Preparation 109 by condensing on the appropriate famine intermediate acid chloride.
- a solution of the product obtained in Preparation 109 (10) is added to a solution of malonyl dichloride (40 mmol) in ether (40 ml) and triethylamine (2 ml). mmol) in ether (160 ml).
- the reaction mixture is concentrated under reduced pressure.
- the residue is dried on a vane pump and then taken up in ether.
- the organic phase is washed with water, dried over magnesium sulfate, concentrated under reduced pressure and then dried on a vane pump.
- the residue is then taken up in 100 ml of 1, 1,2,2-tetrachloroethane.
- Example 116 to 120 the procedure is as in Example 115 starting from the appropriate substrates.
- Example 115 The product of Example 115 (3 mmol) is dissolved in acetic acid (70 ml). After several purges with argon, Pd / C 10% (600 mg) is added and the medium is placed under a hydrogen atmosphere. Stirring is continued at room temperature until the end of the reaction (monitored by TLC) and the palladium is filtered on celite. The acetic acid is evaporated to dryness and the residue is chromatographed on silica gel to yield the title product.
- Example 122 to 126 the procedure is as in Example 121 starting from the appropriate substrates.
- Example 33 The product of Example 33 (10 mmol) and the triethylene glycol are introduced into a bicol. The mixture is heated to 160-170 ° C. under nitrogen and with stirring for five hours. The reaction mixture is poured into ice water and extracted with ethyl acetate. The organic phase is washed with water, dried over calcium chloride. After filtration, the organic phase is concentrated under reduced pressure. The residue is chromatographed on silica gel to yield the title product.
- Example 128 to 132 the procedure is as in Example 127, starting from the appropriate substrates.
- Stage A 2 - ⁇ [(4- ⁇ 2 - [(2-Phenylacetyl) amino] ethyl] -3,4-dihydro-2H-chromen-6-yl) carbonyl] amino ⁇ acetic acid
- Example 39 To the product obtained in Example 39 (4 mmol) dissolved in methanol (10 ml) is added an aqueous solution of 0.5N K2CO3 (10 ml). When the reaction no longer evolves, the solution is acidified to pH 6-7 with a solution of IN hydrochloric acid. The reaction medium is extracted with dichloromethane. The organic phase is washed with water, dried over magnesium sulphate, concentrated under reduced pressure. The residue is chromatographed on silica gel to yield the title product.
- Stage B 2 - ⁇ [(4- ⁇ 2 - [(2-Phenylacetyl) amino] ethyl] -3,4-dihydro-2 ⁇ ' -chromen-6-yl) carbonyl] amino ⁇ acetyl chloride
- stage A The product obtained in stage A (3 mmol) dissolved in thionyl chloride is stirred at 60 ° C under a stream of nitrogen for one hour.
- the thionyl chloride is evaporated under reduced pressure and the residue is dried on a vane pump to yield the title product.
- stage B The product obtained in stage B (3 mmol) in solution in 1,1,2,2-tetrachloroethane (30 ml) is added dropwise to a solution of aluminum chloride (10 mmol) in the same solvent ( 20 ml) under nitrogen.
- the reaction mixture is brought to 60 ° C. with stirring until the reaction no longer progresses, then it is poured into an ice (10 g) / concentrated HCl (0.3 ml) mixture and stirring is continued. during one hour.
- the aqueous phase is extracted twice with chloroform, then the combined organic phases are dried over magnesium sulfate and concentrated under reduced pressure. The residue is chromatographed on silica gel to yield the title product.
- Example 134 to 135 the procedure is as in Example 133, starting from the appropriate reagents.
- Example 136 to 138 the procedure is as in Example 122, starting from the appropriate substrates.
- EXAMPLE 136 N- [2- (4-Oxo-1,3,4,8,9,1 -hexahydro-2 / -pyrano [5,2- / isoquinolin-10-yl) ethyl] -2-phenylacetamide
- Product starting point Example 133
- EXAMPLE 137 N- [2- (4-Oxo-8-naphthyl-1,2,3,4-tetrahydrobenzo [] isoquinoIin-10-yl) ethyl] heptanamide
- Example 127 The product obtained in Example 127 is treated with Lawesson's reagent to yield the title compound Examples 140 to 142 are obtained by proceeding as in Example 139
- Example 11 To a suspension of sodium hydride (2.2 mmol) in methanol (50 ml) at -40 ° C, a solution of the product obtained in Example 11 is added dropwise (2 mmol) in solution in methanol (10 ml). Stirring is continued until the starting material has completely disappeared (approximately 3 hours). At the end of the reaction, the solution is poured into water (30 ml). The reaction medium is concentrated under reduced pressure to a volume of approximately 30 ml, then extraction is carried out with ethyl acetate. The aqueous phase is washed with water, dried over magnesium sulfate and concentrated under reduced pressure. The residue is chromatographed on silica gel to yield the title product.
- Example 144 the procedure is as in Example 143.
- Acute toxicity was assessed after oral administration to groups of 8 mice (26 ⁇ 2 grams). The animals were observed at regular intervals during the first day and daily during the two weeks following the treatment. The LD 50, resulting in the death of 50% of the animals, was evaluated and showed the low toxicity of the compounds of the invention
- the melatonin receptor binding studies of the compounds of the invention were carried out according to conventional techniques on the cells of the sheep pars tuberalis.
- the pars tuberalis of the adenohypophysis is indeed characterized, in mammals, by a high density of melatonin receptors (Journal of Neuroendocrinology, I, pp. 1-4, 1989)
- EXAMPLE C 1. Study of binding to the mti and MT 2 melatonin receptors
- the experiments for binding to the mti or MT 2 receptors are carried out using 2- [ 125 I] -iodomelatonin as the reference radioligand.
- the radioactivity retained is determined using a liquid scintillation counter.
- the binding experiments on the MT 3 sites are carried out on hamster brain membranes using 2- [ 125 I] iodomelatonin as radioligand.
- the membranes are incubated for 30 minutes with 2- [ 125 I] iodomelatonin at a temperature of 4 ° C. and different concentrations of the compounds to be tested. After incubation, the membranes are quickly filtered and then washed with cold buffer using a filtration system. The fixed radioactivity is measured by a scintillation counter.
- the values of IC 5 o concentration inhibiting by 50% the specific binding are calculated from competition curves using a nonlinear regression model.
- the IC 50 values found for the compounds of the invention attest to a bond for one or the other of the receptor subtypes, these values being ⁇ 10 ⁇ M.
- the effects of the molecules are tested on many parameters and, in particular, on the circadian rhythms of locomotor activity which represent a reliable marker of the activity of the endogenous circadian clock.
- the rats receive a daily administration of the test molecule.
- Software allows: - to measure the duration and intensity of the activity, the period of the rhythm in the animals in free course and during the treatment,
- circadian and non-circadian components possibly highlighting by spectral analysis the existence of circadian and non-circadian components (ultradians for example).
- the compounds of the invention are tested in a behavioral model, the test of clear / dark cages, which makes it possible to reveal the anxiolytic activity of the molecules.
- the device consists of two polyvinyl boxes covered with Plexiglas. One of these boxes is obscure. A lamp is placed above the other box giving a light intensity in the center thereof of approximately 4000 lux. An opaque plastic tunnel separates the light box from the dark box. The animals are tested individually during a 5 min session. The floor of each box is cleaned between each session. At the start of each test, the mouse is placed in the tunnel, facing the dark box. The time spent by the mouse in the lit box and the number of transitions through the tunnel are recorded after the first entry in the dark box.
- the compounds of the invention significantly increase the time spent in the lighted cage as well as the number of transitions, which shows the anxiolytic activity of the derivatives of the invention.
- the compounds of the invention were tested in vitro on the rat caudal artery.
- Melatoninergic receptors are present on these vessels which makes them a pharmacological model relevant to study the activity of melatoninergic ligands. Stimulation of receptors can induce either vasoconstriction or dilation depending on the arterial segment studied.
- Rats aged 1 month are accustomed for 2 to 3 weeks to a light / dark cycle 12h / 12h.
- the caudal artery is isolated and maintained in a richly oxygenated environment.
- the arteries are then cannulated at both ends, suspended vertically in an organ chamber in an appropriate medium and perfused via their proximal end. Changes in pressure in the infusion rate allow the vasoconstrictor or vasodilator effect of the compounds to be assessed.
- the activity of the compounds is evaluated on segments pre-contracted by phenylephrine (1 ⁇ M).
- a concentration-response curve is determined in a non-cumulative manner by adding a concentration of the compound studied on the pre-contracted segment. When the observed effect has reached equilibrium, the medium is changed and the preparation left 20 minutes before the addition of the same concentration of phenylephrine and a new concentration of the compound studied.
- the compounds of the invention significantly modify the diameter of the caudal arteries preconstructed by phenylephrine.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002331877A CA2331877C (fr) | 1998-05-12 | 1999-05-10 | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP99918037A EP1077928B1 (fr) | 1998-05-12 | 1999-05-10 | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US09/700,056 US6605632B1 (en) | 1998-05-12 | 1999-05-10 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them |
DE69933147T DE69933147T2 (de) | 1998-05-12 | 1999-05-10 | Sustiuierte cyclische verbindungen, verfahren zu ihrer herstellung sowie sie enthaltende pharmazeutische zusammesetzungen |
AU36104/99A AU747301B2 (en) | 1998-05-12 | 1999-05-10 | Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them |
AT99918037T ATE312073T1 (de) | 1998-05-12 | 1999-05-10 | Sustiuierte cyclische verbindungen, verfahren zu ihrer herstellung sowie sie enthaltende pharmazeutische zusammesetzungen |
JP2000548300A JP2002514620A (ja) | 1998-05-12 | 1999-05-10 | 新しい置換環状化合物、これらの製造方法及びこれらを含む薬剤組成物 |
PL99344048A PL195613B1 (pl) | 1998-05-12 | 1999-05-10 | Nowe podstawione związki cykliczne, sposób ich wytwarzania, kompozycje farmaceutyczne je zawierające oraz zastosowanie kompozycji |
BR9911783-5A BR9911783A (pt) | 1998-05-12 | 1999-05-10 | Compostos cìclicos substituìdos, processo para sua preparação e composições farmacêuticas que os contêm |
NZ507692A NZ507692A (en) | 1998-05-12 | 1999-05-10 | Retroamide chain benzofuran and benzothiophene compounds substituted by amides or carbamates for use in melatonergic system disorders |
HU0101800A HUP0101800A3 (en) | 1998-05-12 | 1999-05-10 | Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them |
NO20005715A NO20005715L (no) | 1998-05-12 | 2000-11-13 | Nye substituerte cykliske forbindelser, fremgangsmåte ved deres fremstilling og farmasöytiske sammensetninger inneholdende dem |
US10/462,331 US7183318B2 (en) | 1998-05-12 | 2003-06-16 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR98/05957 | 1998-05-12 | ||
FR9805957A FR2778662B1 (fr) | 1998-05-12 | 1998-05-12 | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Related Child Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/700,056 A-371-Of-International US6605632B1 (en) | 1998-05-12 | 1999-05-10 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them |
US09700056 A-371-Of-International | 1999-05-10 | ||
US10/462,331 Division US7183318B2 (en) | 1998-05-12 | 2003-06-16 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them |
US10/462,326 Division US20040002490A1 (en) | 1998-05-12 | 2003-06-16 | Substituted cyclic compounds, preparation method and pharmaceutical compositions containing them |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999058496A1 true WO1999058496A1 (fr) | 1999-11-18 |
Family
ID=9526252
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/001101 WO1999058496A1 (fr) | 1998-05-12 | 1999-05-10 | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
PCT/FR1999/001100 WO1999058495A1 (fr) | 1998-05-12 | 1999-05-10 | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/001100 WO1999058495A1 (fr) | 1998-05-12 | 1999-05-10 | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Country Status (18)
Country | Link |
---|---|
US (6) | US6872851B1 (fr) |
EP (2) | EP1077928B1 (fr) |
JP (2) | JP2002514620A (fr) |
CN (2) | CN1304400A (fr) |
AT (2) | ATE312073T1 (fr) |
AU (2) | AU747301B2 (fr) |
BR (2) | BR9911783A (fr) |
CA (2) | CA2331877C (fr) |
DE (2) | DE69933149T2 (fr) |
DK (2) | DK1077927T3 (fr) |
ES (2) | ES2255260T3 (fr) |
FR (1) | FR2778662B1 (fr) |
HU (2) | HUP0101800A3 (fr) |
NO (2) | NO20005715L (fr) |
NZ (2) | NZ507692A (fr) |
PL (2) | PL195613B1 (fr) |
WO (2) | WO1999058496A1 (fr) |
ZA (2) | ZA200006528B (fr) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006019497A2 (fr) * | 2004-06-17 | 2006-02-23 | Neurocrine Biosciences, Inc. | Composes somniferes et procedes associes |
US7728140B2 (en) | 2003-12-24 | 2010-06-01 | Pfizer Italia S.R.L. | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them |
US7888508B2 (en) | 2003-12-24 | 2011-02-15 | Pfizer Italia S.R.L. | Pyrrolo[2,3-B]pyridine derivatives active as kinase inhibitors |
US9266886B2 (en) | 2014-02-03 | 2016-02-23 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9796710B2 (en) | 2014-10-14 | 2017-10-24 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
US10829481B2 (en) | 2016-01-29 | 2020-11-10 | Vitae Pharmaceuticals, Llc | Benzimidazole derivatives as modulators of ROR-gamma |
US10913739B2 (en) | 2017-07-24 | 2021-02-09 | Vitae Pharmaceuticals, LLC (121374) | Inhibitors of RORγ |
US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
US11186573B2 (en) | 2017-07-24 | 2021-11-30 | Vitae Pharmaceuticals, Llc | Inhibitors of ROR gamma |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPO274596A0 (en) * | 1996-10-04 | 1996-10-31 | Armstrong, Stuart Maxwell | Method for the treatment of neurological or neuropsychiatric disorders |
FR2778662B1 (fr) * | 1998-05-12 | 2000-06-16 | Adir | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US6569879B2 (en) * | 2000-02-18 | 2003-05-27 | Merck & Co., Inc. | Aryloxyacetic acids for diabetes and lipid disorders |
FR2814165B1 (fr) * | 2000-09-15 | 2002-11-22 | Adir | Nouveaux derives biphenyles substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
IL156304A0 (en) * | 2000-12-11 | 2004-01-04 | Tularik Inc | Cxcr3 antagonists |
US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
FR2853649B1 (fr) * | 2003-04-09 | 2006-07-14 | Servier Lab | Nouveaux derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2857011B1 (fr) * | 2003-07-04 | 2005-09-16 | Servier Lab | Nouveaux derives du benzothiophene 2-thiosubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
ES2338668T3 (es) * | 2004-05-05 | 2010-05-11 | F. Hoffmann-La Roche Ag | Arilsulfonil benzodioxanos utiles para la modulacion del receptor 5-ht6 y del receptor 5-ht2a o ambos. |
US7375102B2 (en) | 2004-06-28 | 2008-05-20 | Amgen Sf, Llc | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use |
US7271271B2 (en) * | 2004-06-28 | 2007-09-18 | Amgen Sf, Llc | Imidazolo-related compounds, compositions and methods for their use |
US7939538B2 (en) | 2004-06-28 | 2011-05-10 | Amgen Inc. | Compounds, compositions and methods for prevention and treatment of inflammatory and immunoregulatory disorders and diseases |
RU2388748C2 (ru) * | 2004-12-21 | 2010-05-10 | Ф. Хоффманн-Ля Рош Аг | Производные тетралина и индана и их применения в качестве антагонистов 5-нт |
WO2006066756A1 (fr) | 2004-12-21 | 2006-06-29 | F. Hoffmann-La Roche Ag | Derives de chromane utiles dans le traitement des troubles du systeme nerveux central |
KR100899061B1 (ko) | 2004-12-21 | 2009-05-25 | 에프. 호프만-라 로슈 아게 | 테트랄린 및 인단 유도체 및 이의 용도 |
AU2005318596B2 (en) * | 2004-12-21 | 2010-12-23 | F. Hoffmann-La Roche Ag | Chroman derivatives and their use as 5-HT receptor ligands |
DK1831159T3 (da) * | 2004-12-21 | 2010-03-22 | Hoffmann La Roche | Tetralin og indanderivater samt anvendelser deraf |
CN101300246A (zh) * | 2005-11-03 | 2008-11-05 | 弗·哈夫曼-拉罗切有限公司 | 作为5-ht6抑制剂的芳基磺酰基色满类化合物作为蛋白激酶抑制剂的吲哚基马来酰亚胺衍生物 |
US8337721B2 (en) | 2005-12-02 | 2012-12-25 | Vanderbilt University | Broad-emission nanocrystals and methods of making and using same |
CN102633783A (zh) * | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
KR101064001B1 (ko) * | 2006-06-20 | 2011-09-08 | 에프. 호프만-라 로슈 아게 | 아릴설폰아미딜 테트랄린 유도체 및 이의 용도 |
BRPI0713736A2 (pt) * | 2006-06-20 | 2014-11-18 | Hoffmann La Roche | Derivados de tetralina e indano e emprego destes |
BRPI0713742A2 (pt) | 2006-06-20 | 2013-02-13 | Hoffmann La Roche | derivados de arilsulfonila naftaleno e usos destes |
US20100216796A1 (en) * | 2007-10-04 | 2010-08-26 | Solomon Kattar | N-hydroxy-naphthalene dicarboxamide and n-hydroxy-biphenyl-dicarboxamide compounds as histone deacetylase inhibitors |
EP2163551B1 (fr) | 2008-09-08 | 2011-11-16 | Cadila Pharmaceuticals Ltd. | Procédé amélioré pour la préparation d'hydrochlorure de nebivolol |
CN101481321B (zh) * | 2009-02-27 | 2012-04-18 | 上海医药工业研究院 | 阿戈美拉汀卤化氢复合物及其制备方法 |
CN104292125B (zh) * | 2014-08-14 | 2016-06-01 | 广东东阳光药业有限公司 | 萘衍生物及其在药物上的应用 |
EP3253753A4 (fr) | 2015-01-20 | 2018-06-27 | Xoc Pharmaceuticals, Inc | Composés d'ergoline et leurs utilisations |
US9676776B2 (en) | 2015-01-20 | 2017-06-13 | Xoc Pharmaceuticals, Inc. | Isoergoline compounds and uses thereof |
AU2018275873A1 (en) | 2017-06-01 | 2019-12-19 | Xoc Pharmaceuticals, Inc. | Ergoline derivatives for use in medicine |
CN108156986A (zh) * | 2018-01-04 | 2018-06-15 | 山东农业大学 | 外源褪黑素对苹果矮化自根砧木幼苗臭氧胁迫缓解效应的应用 |
CA3220039A1 (fr) | 2021-06-14 | 2022-12-22 | Jr. David St. Jean | Derives d'uree pouvant etre utilises pour traiter le cancer |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0530087A1 (fr) * | 1991-08-23 | 1993-03-03 | Adir Et Compagnie | Nouvelles naphtyléthylurées et naphtyléthylthiourées, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
EP0562956A1 (fr) * | 1992-03-27 | 1993-09-29 | Adir Et Compagnie | Nouvelles naphtylalkylamines leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
EP0662471A2 (fr) * | 1993-12-07 | 1995-07-12 | Adir Et Compagnie | Dérivés naphtaléniques ayant une affinité pour les récepteurs de la mélatonine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
EP0728738A1 (fr) * | 1995-02-24 | 1996-08-28 | Bristol-Myers Squibb Company | Tétralinyl- et indanyl-éthyle amides ayant une activité mélatonergique |
EP0745583A1 (fr) * | 1995-05-31 | 1996-12-04 | Adir Et Compagnie | Composés alkoxy-aryles ayant une affinité pour les récepteurs mélatoninergiques, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent |
EP0745584A1 (fr) * | 1995-05-31 | 1996-12-04 | Adir Et Compagnie | Composés arylalkyl(thio) carboxamides ayant une affinité pour des récepteurs mélatoninergiques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663347A (en) * | 1983-10-31 | 1987-05-05 | Merck Frosst Canada, Inc. | Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis |
FR2705095B1 (fr) * | 1993-05-12 | 1995-06-23 | Adir | Nouveaux indoles substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
GB9313913D0 (en) * | 1993-07-06 | 1993-08-18 | Smithkline Beecham Plc | Novel compounds |
US5350748A (en) * | 1993-08-18 | 1994-09-27 | Warner-Lambert Company | 3-thio or amino substituted-benzo[b]thiophene-2-carboxamides and 3-oxygen, thio, or amino substituted-benzofuran-2-carboxamides as inhibitors of cell adhesion |
AU3399895A (en) * | 1994-09-12 | 1996-03-29 | Takeda Chemical Industries Ltd. | Benzocycloalkene compounds, their production and use |
US5863936A (en) * | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
JP2000501411A (ja) * | 1995-12-05 | 2000-02-08 | ダーウィン・ディスカバリー・リミテッド | ベンゾフランカルボキサミドおよびスルホンアミド |
FR2778662B1 (fr) * | 1998-05-12 | 2000-06-16 | Adir | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
KR101012391B1 (ko) | 2008-11-11 | 2011-02-09 | 엘지전자 주식회사 | 무선 통신 시스템에 있어서, 하향링크로 서브프레임 지정 정보를 전송하는 방법 |
-
1998
- 1998-05-12 FR FR9805957A patent/FR2778662B1/fr not_active Expired - Fee Related
-
1999
- 1999-05-10 EP EP99918037A patent/EP1077928B1/fr not_active Expired - Lifetime
- 1999-05-10 JP JP2000548300A patent/JP2002514620A/ja active Pending
- 1999-05-10 US US09/700,098 patent/US6872851B1/en not_active Expired - Fee Related
- 1999-05-10 CN CN99806830A patent/CN1304400A/zh active Pending
- 1999-05-10 AT AT99918037T patent/ATE312073T1/de not_active IP Right Cessation
- 1999-05-10 HU HU0101800A patent/HUP0101800A3/hu unknown
- 1999-05-10 EP EP99918036A patent/EP1077927B1/fr not_active Expired - Lifetime
- 1999-05-10 PL PL99344048A patent/PL195613B1/pl unknown
- 1999-05-10 AU AU36104/99A patent/AU747301B2/en not_active Ceased
- 1999-05-10 CN CN99806053A patent/CN1300277A/zh active Pending
- 1999-05-10 CA CA002331877A patent/CA2331877C/fr not_active Expired - Fee Related
- 1999-05-10 WO PCT/FR1999/001101 patent/WO1999058496A1/fr active IP Right Grant
- 1999-05-10 AT AT99918036T patent/ATE312072T1/de not_active IP Right Cessation
- 1999-05-10 ES ES99918036T patent/ES2255260T3/es not_active Expired - Lifetime
- 1999-05-10 ES ES99918037T patent/ES2255261T3/es not_active Expired - Lifetime
- 1999-05-10 DK DK99918036T patent/DK1077927T3/da active
- 1999-05-10 US US09/700,056 patent/US6605632B1/en not_active Expired - Fee Related
- 1999-05-10 NZ NZ507692A patent/NZ507692A/en unknown
- 1999-05-10 PL PL99344012A patent/PL344012A1/xx unknown
- 1999-05-10 BR BR9911783-5A patent/BR9911783A/pt not_active Application Discontinuation
- 1999-05-10 DK DK99918037T patent/DK1077928T3/da active
- 1999-05-10 HU HU0101813A patent/HUP0101813A3/hu unknown
- 1999-05-10 JP JP2000548299A patent/JP2002514619A/ja active Pending
- 1999-05-10 DE DE69933149T patent/DE69933149T2/de not_active Expired - Fee Related
- 1999-05-10 NZ NZ507691A patent/NZ507691A/en unknown
- 1999-05-10 WO PCT/FR1999/001100 patent/WO1999058495A1/fr active IP Right Grant
- 1999-05-10 BR BR9911771-1A patent/BR9911771A/pt not_active Application Discontinuation
- 1999-05-10 CA CA002331870A patent/CA2331870C/fr not_active Expired - Fee Related
- 1999-05-10 DE DE69933147T patent/DE69933147T2/de not_active Expired - Fee Related
- 1999-05-10 AU AU36103/99A patent/AU748567B2/en not_active Ceased
-
2000
- 2000-11-10 ZA ZA200006528A patent/ZA200006528B/en unknown
- 2000-11-10 ZA ZA200006529A patent/ZA200006529B/en unknown
- 2000-11-13 NO NO20005715A patent/NO20005715L/no not_active Application Discontinuation
- 2000-11-13 NO NO20005714A patent/NO20005714D0/no not_active Application Discontinuation
-
2003
- 2003-06-16 US US10/462,331 patent/US7183318B2/en not_active Expired - Fee Related
- 2003-06-16 US US10/462,326 patent/US20040002490A1/en not_active Abandoned
-
2004
- 2004-09-23 US US10/948,410 patent/US7115752B2/en not_active Expired - Fee Related
- 2004-09-23 US US10/947,757 patent/US7126012B2/en not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0530087A1 (fr) * | 1991-08-23 | 1993-03-03 | Adir Et Compagnie | Nouvelles naphtyléthylurées et naphtyléthylthiourées, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
EP0562956A1 (fr) * | 1992-03-27 | 1993-09-29 | Adir Et Compagnie | Nouvelles naphtylalkylamines leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
EP0662471A2 (fr) * | 1993-12-07 | 1995-07-12 | Adir Et Compagnie | Dérivés naphtaléniques ayant une affinité pour les récepteurs de la mélatonine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent |
EP0728738A1 (fr) * | 1995-02-24 | 1996-08-28 | Bristol-Myers Squibb Company | Tétralinyl- et indanyl-éthyle amides ayant une activité mélatonergique |
EP0745583A1 (fr) * | 1995-05-31 | 1996-12-04 | Adir Et Compagnie | Composés alkoxy-aryles ayant une affinité pour les récepteurs mélatoninergiques, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent |
EP0745584A1 (fr) * | 1995-05-31 | 1996-12-04 | Adir Et Compagnie | Composés arylalkyl(thio) carboxamides ayant une affinité pour des récepteurs mélatoninergiques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8198298B2 (en) | 2003-12-24 | 2012-06-12 | Pfizer Italia S.R.L. | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors |
US7728140B2 (en) | 2003-12-24 | 2010-06-01 | Pfizer Italia S.R.L. | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them |
US7888508B2 (en) | 2003-12-24 | 2011-02-15 | Pfizer Italia S.R.L. | Pyrrolo[2,3-B]pyridine derivatives active as kinase inhibitors |
US8106069B2 (en) | 2003-12-24 | 2012-01-31 | Pfizer Italia S.R.L. | Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors and pharmaceutical compositions comprising them |
WO2006019497A2 (fr) * | 2004-06-17 | 2006-02-23 | Neurocrine Biosciences, Inc. | Composes somniferes et procedes associes |
US7393865B2 (en) | 2004-06-17 | 2008-07-01 | Neurocrine Biosciences, Inc. | Sleep inducing compounds and methods relating thereto |
WO2006019497A3 (fr) * | 2004-06-17 | 2006-04-20 | Neurocrine Biosciences Inc | Composes somniferes et procedes associes |
US11535614B2 (en) | 2014-02-03 | 2022-12-27 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10399976B2 (en) | 2014-02-03 | 2019-09-03 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9624217B2 (en) | 2014-02-03 | 2017-04-18 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10807980B2 (en) | 2014-02-03 | 2020-10-20 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9266886B2 (en) | 2014-02-03 | 2016-02-23 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10047085B2 (en) | 2014-02-03 | 2018-08-14 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9796710B2 (en) | 2014-10-14 | 2017-10-24 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10087184B2 (en) | 2014-10-14 | 2018-10-02 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of RORγ |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US11001583B2 (en) | 2014-11-05 | 2021-05-11 | Vitae Pharmaceuticals, Llc | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
US10829448B2 (en) | 2015-08-05 | 2020-11-10 | Vitae Pharmaceuticals, Llc | Substituted benzoimidazoles as modulators of ROR-γ |
US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
US10829481B2 (en) | 2016-01-29 | 2020-11-10 | Vitae Pharmaceuticals, Llc | Benzimidazole derivatives as modulators of ROR-gamma |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US10913739B2 (en) | 2017-07-24 | 2021-02-09 | Vitae Pharmaceuticals, LLC (121374) | Inhibitors of RORγ |
US11186573B2 (en) | 2017-07-24 | 2021-11-30 | Vitae Pharmaceuticals, Llc | Inhibitors of ROR gamma |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2331877C (fr) | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
FR2689124A1 (fr) | Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. | |
EP0708099B1 (fr) | Nouveaux composés amides tricycliques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
EP1057826B1 (fr) | Dérivés carboxamides dimériques substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
AU755115B2 (en) | New cyclic compounds having a cycloalkylene chain, a process for their preparation and pharmaceutical compositions containing them | |
CA2462939C (fr) | Nouveaux derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1038863B1 (fr) | Nouveaux dérivés dimériques substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent | |
CA2419934C (fr) | Derives biphenyles substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
CA2309771C (fr) | Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1558566A1 (fr) | Nouveaux derives du phenylnaphtalene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99806053.4 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BR CA CN HU JP NO NZ PL US ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999918037 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 507692 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2331877 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000/06529 Country of ref document: ZA Ref document number: 36104/99 Country of ref document: AU Ref document number: 200006529 Country of ref document: ZA Ref document number: 09700056 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999918037 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 36104/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999918037 Country of ref document: EP |